Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 16/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.37 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545158 | 0.86 | EHMT2 (0.40) | EHMT2EHMT1KLKB1 | |
| SCHEMBL17544811 | 0.85 | EHMT2 (0.41) | EHMT2EHMT1KLKB1 | |
| SCHEMBL17670405 | 0.83 | EHMT2 (0.39) | EHMT2EHMT1 | |
| SCHEMBL17549943 | 0.81 | EHMT2 (0.38) | EHMT2EHMT1KLKB1 | |
| SCHEMBL17670431 | 0.79 | USP2 (0.39) | EHMT2EHMT1 | |
| SCHEMBL17545013 | 0.79 | EHMT2 (0.37) | EHMT2EHMT1 | |
| SCHEMBL17544666 | 0.78 | EHMT2 (0.44) | EHMT2EHMT1KLKB1 | |
| SCHEMBL17670429 | 0.77 | EHMT2 (0.41) | EHMT2EHMT1KLKB1 | |
| SCHEMBL17544728 | 0.77 | EHMT2 (0.44) | EHMT2EHMT1 | |
| SCHEMBL17549921 | 0.76 | CASR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | EHMT2 31/4885EHMT1 26/4885F2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.